{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:55:09Z","timestamp":1786996509438,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.schres.2020.09.007","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T07:58:56Z","timestamp":1601020736000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4559-3666","authenticated-orcid":false,"given":"Manuel","family":"Morrens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"De Picker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarl K.","family":"Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violette","family":"Coppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2020.09.007_bb0005","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.bcp.2012.12.014","article-title":"Kynurenic acid as an antagonist of \u03b17 nicotinic acetylcholine receptors in the brain: facts and challenges","volume":"85","author":"Albuquerque","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.schres.2020.09.007_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0278-5846(98)00089-X","article-title":"Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan","volume":"23","author":"Aymard","year":"1999","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/0269881108089583","article-title":"Kynurenine pathway in psychosis: evidence of increased tryptophan degradation","author":"Barry","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.09.007_bb0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00726-018-2579-6","article-title":"Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case\u2013control study","author":"Cao","year":"2018","journal-title":"Amino Acids"},{"key":"10.1016\/j.schres.2020.09.007_bb0025","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/0006-3223(92)90157-U","article-title":"Is plasma serine a marker for psychosis?","volume":"31","author":"Carl","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.psychres.2012.08.021","article-title":"CSF kynurenic acid and suicide risk in schizophrenia spectrum psychosis","volume":"205","author":"Carlborg","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0035","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/npp.2016.66","article-title":"Tryptophan metabolism and white matter integrity in schizophrenia","volume":"41","author":"Chiappelli","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2020.09.007_bb0040","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41386-018-0038-4","article-title":"Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia","volume":"43","author":"Chiappelli","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2020.09.007_bb0045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1017\/S1461145710001689","article-title":"3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia","volume":"14","author":"Condray","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2020.09.007_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.schres.2019.02.020","article-title":"Serum xanthurenic acid levels: reduced in subjects at ultra high risk for psychosis","volume":"208","author":"Curto","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0055","first-page":"2971","article-title":"Immune and neuroendocrine trait and state markers in psychotic illness: decreased kynurenines marking psychotic exacerbations. Front","volume":"10","author":"De Picker","year":"2019","journal-title":"Immunol"},{"key":"10.1016\/j.schres.2020.09.007_bb0060","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3389\/fimmu.2019.02971","article-title":"Immune and neuroendocrine trait and state markers in psychotic illness: decreased kynurenines marking psychotic exacerbations","volume":"10","author":"De Picker","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.schres.2020.09.007_bb0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbi.2018.11.318","article-title":"State-associated changes in longitudinal [F]-PBR111 TSPO PET imaging of psychosis patients: evidence for the accelerated ageing hypothesis?","volume":"77","author":"De Picker","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.09.007_bb0070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0304-3940(01)02242-X","article-title":"Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia","volume":"313","author":"Erhardt","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2020.09.007_bb0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","article-title":"The kynurenine pathway in schizophrenia and bipolar disorder","volume":"112","author":"Erhardt","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2020.09.007_bb0080","doi-asserted-by":"crossref","first-page":"17799","DOI":"10.1038\/srep17799","article-title":"Xanthurenic acid activates mGlu2\/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia","volume":"5","author":"Fazio","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2020.09.007_bb0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mad.2006.11.016","article-title":"Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans","volume":"128","author":"Franceschi","year":"2007","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.schres.2020.09.007_bb0090","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2020.09.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101652","article-title":"Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients","volume":"9","author":"Fukushima","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2020.09.007_bb0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1471-4159.1978.tb07815.x","article-title":"Synthesis and metabolism of L-kynurenine in rat brain","volume":"30","author":"G\u00e1l","year":"1978","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2020.09.007_bb0105","article-title":"Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism","author":"Gao","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.schres.2020.09.007_bb0110","doi-asserted-by":"crossref","first-page":"36554","DOI":"10.1074\/jbc.M113.503813","article-title":"Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain","volume":"288","author":"Giorgini","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.schres.2020.09.007_bb0115","article-title":"Peripheral cortisol and inflammatory response to a psychosocial stressor in people with schizophrenia","volume":"2","author":"Glassman","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.schres.2020.09.007_bb0120","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.14104","article-title":"Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia","volume":"142","author":"Havelund","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2020.09.007_bb0125","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3389\/fpsyg.2017.01561","article-title":"The relationships among tryptophan, kynurenine, indoleamine 2,3-dioxygenase, depression, and neuropsychological performance","volume":"8","author":"Hestad","year":"2017","journal-title":"Front. Psychol."},{"issue":"Pt 5","key":"10.1016\/j.schres.2020.09.007_bb0130","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"key":"10.1016\/j.schres.2020.09.007_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/NDT.S239763","article-title":"Increased plasma kynurenic acid levels are associated with impaired attention\/vigilance and social cognition in patients with schizophrenia","volume":"16","author":"Huang","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2020.09.007_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2019.03.015","article-title":"Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer\u2019s disease and relationship to amyloid-\u03b2 and tau","volume":"80","author":"Jacobs","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.schres.2020.09.007_bb0145","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-018-1838-8","article-title":"Kynurenine is correlated with IL-1\u03b2 in plasma of schizophrenia patients","author":"Joaquim","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.schres.2020.09.007_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/IJTR.S16800","article-title":"Imbalanced kynurenine pathway in schizophrenia","volume":"7","author":"Kegel","year":"2014","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000213565","article-title":"Cytokine changes and tryptophan metabolites in medication-na\u00efve and medication-free schizophrenic patients","volume":"59","author":"Kim","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2020.09.007_bb0160","article-title":"Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia","author":"Kindler","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0165","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1038\/tp.2014.19","article-title":"A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study","volume":"4","author":"Koike","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.psychres.2010.07.013","article-title":"Decreased plasma tryptophan and tryptophan\/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration","volume":"185","author":"Lee","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jagp.2016.09.009","article-title":"Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables","author":"Lee","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fpsyt.2018.00155","article-title":"Profiling of amino acids and their derivatives biogenic amines before and after antipsychotic treatment in first-episode psychosis","volume":"9","author":"Leppik","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0185","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0190","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0195","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/schbul\/sbq086","article-title":"Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia","volume":"38","author":"Linderholm","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.09.007_bb0200","series-title":"Handbook of Schizophrenia Spectrum Disorders","article-title":"Diagnosis and classification of the schizophrenia spectrum disorders","volume":"vol. I","author":"Mamah","year":"2011"},{"key":"10.1016\/j.schres.2020.09.007_bb0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbi.2015.11.003","article-title":"Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder","volume":"53","author":"Meier","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.09.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/S0920-9964(03)80603-5","article-title":"Tryptophan 2,3-dioxygenase is upregulated in the cortex of individuals with schizophrenia","author":"Miller","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0215","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein levels in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2020.09.007_bb0225","first-page":"1","article-title":"Do immune dysregulations and oxidative damage drive mood and psychotic disorders?","author":"Morrens","year":"2019","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2020.09.007_bb0230","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1742-4658.2012.08551.x","article-title":"Kynurenines: from the perspective of major psychiatric disorders","volume":"279","author":"Myint","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.schres.2020.09.007_bb0235","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbi.2011.05.005","article-title":"Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-na\u00efve and medication-free schizophrenic patients","volume":"25","author":"Myint","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.09.007_bb0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2005.07.013","article-title":"Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia","volume":"80","author":"Nilsson","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0245","doi-asserted-by":"crossref","first-page":"256","DOI":"10.14336\/AD.2014.0500256","article-title":"Accelerated aging in schizophrenia patients: the potential role of oxidative stress","volume":"5","author":"Okusaga","year":"2014","journal-title":"Aging Dis."},{"key":"10.1016\/j.schres.2020.09.007_bb0250","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2967\/jnumed.117.203315","article-title":"F-PBR111 PET imaging in healthy controls and schizophrenia: test-retest reproducibility and quantification of neuroinflammation","volume":"59","author":"Ottoy","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.schres.2020.09.007_bb0255","doi-asserted-by":"crossref","DOI":"10.15761\/ICM.1000105","article-title":"Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients","volume":"1","author":"Oxenkrug","year":"2017","journal-title":"Integr Clin Med"},{"key":"10.1016\/j.schres.2020.09.007_bb0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2019.07.038","article-title":"Plasma xanthurenic acid in a context of insulin resistance and obesity in schizophrenia","volume":"211","author":"Oxenkrug","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0265","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1017\/S1461145714000157","article-title":"Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome","volume":"17","author":"Paredes","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2020.09.007_bb0270","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/schbul\/sbw221","article-title":"Kynurenic acid in schizophrenia: a systematic review and meta-analysis","volume":"43","author":"Plitman","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.09.007_bb0275","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archpsyc.1983.01790060047006","article-title":"Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia","volume":"40","author":"Potkin","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/mp.2009.116","article-title":"CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression","volume":"15","author":"Raison","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-1781(90)90003-N","article-title":"Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects","volume":"34","author":"Rao","year":"1990","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0290","first-page":"1","article-title":"The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment. Nord","author":"Ribeiro-Santos","year":"2019","journal-title":"J. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/15622975.2018.1433878","article-title":"The role of the gut microbiota in schizophrenia: current and future perspectives","volume":"19","author":"Rodrigues-Amorim","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0300","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","article-title":"Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia","volume":"37","author":"Sathyasaikumar","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.09.007_bb0305","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/npp.2014.194","article-title":"Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder","volume":"40","author":"Savitz","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2020.09.007_bb0310","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/15622975.2016.1224929","article-title":"Consensus paper of the WFSBP Task Force on Biological Markers: criteria for biomarkers and endophenotypes of schizophrenia, part III: molecular mechanisms","volume":"18","author":"Schmitt","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0315","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","article-title":"Increased cortical kynurenate content in schizophrenia","volume":"50","author":"Schwarcz","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0320","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1503\/jpn.140126","article-title":"Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia\u2014significance for activation of the kynurenine pathway","volume":"40","author":"Schwieler","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2020.09.007_bb0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41398-019-0378-9","article-title":"Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls","volume":"9","author":"Sellgren","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0330","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.schres.2016.12.026","article-title":"Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia","volume":"185","author":"Shovestul","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0335","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1471-4159.1990.tb13296.x","article-title":"Uptake of kynurenine into rat brain slices","volume":"54","author":"Speciale","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2020.09.007_bb0340","article-title":"Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders","volume":"1\u201312","author":"Steen","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2020.09.007_bb0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jnc.14907","article-title":"Does kynurenic acid act on nicotinic receptors? An assessment of the evidence","volume":"152","author":"Stone","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2020.09.007_bb0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12640-017-9714-0","article-title":"Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-\u03b1, and IL-4 with clinical symptoms during acute relapse of schizophrenia","volume":"32","author":"Szymona","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.schres.2020.09.007_bb0355","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jrsm.1339","article-title":"Current practices in meta-regression in psychology, education, and medicine","volume":"10","author":"Tipton","year":"2019","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.schres.2020.09.007_bb0360","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000054937","article-title":"Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine","volume":"44","author":"Tortorella","year":"2001","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2020.09.007_bb0365","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00702-004-0200-5","article-title":"Amino acids in schizophrenia: evidence for lower tryptophan availability during treatment with atypical antipsychotics?","volume":"112","author":"van der Heijden","year":"2005","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.schres.2020.09.007_bb0370","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.09.007_bb0375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.09.007_bb0380","article-title":"Association between C-reactive protein and risk of schizophrenia: an updated meta-analysis","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.schres.2020.09.007_bb0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archgenpsychiatry.2011.71","article-title":"Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes","volume":"68","author":"Wonodi","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0390","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1038\/tp.2017.88","article-title":"Serum kynurenic acid is reduced in affective psychosis","volume":"7","author":"Wurfel","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0395","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/08039488.2014.984755","article-title":"Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder","volume":"69","author":"Wysoki\u0144ski","year":"2015","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.09.007_bb0400","doi-asserted-by":"crossref","DOI":"10.1139\/jpn.090171","article-title":"Bioanalytical inaccuracy: a threat to the integrity and efficiency of research","author":"Young","year":"2010","journal-title":"J. Psychiatry Neurosci."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420304655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420304655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:40:51Z","timestamp":1760298051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420304655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":80,"alternative-id":["S0920996420304655"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.09.007","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}